Gastroenterology
Volume 139, Issue 1 , Pages 154-162.e4 , July 2010

Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling

  • Jordan J. Feld

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Toronto Western Hospital Liver Centre, University of Toronto, Toronto, Canada
    • ,
  • Glen A. Lutchman

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Stanford University School of Medicine, Stanford, California
    • ,
  • Theo Heller

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Koji Hara

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Julie K. Pfeiffer

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, Texas
    • ,
  • Richard D. Leff

      Affiliations

    • School of Pharmacy, Texas Tech University Health Sciences Center & Children's Medical Center, Dallas, Texas
    • ,
  • Claudia Meek

      Affiliations

    • School of Pharmacy, Texas Tech University Health Sciences Center & Children's Medical Center, Dallas, Texas
    • ,
  • Maria Rivera

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Myung Ko

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Christopher Koh

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Yaron Rotman

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Marc G. Ghany

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Vanessa Haynes–Williams

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • Avidan U. Neumann

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • ,
  • T. Jake Liang

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationReprint requests Address requests for reprints to: T. Jake Liang, MD, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 10, Room 9B16, 10 Center Drive, MSC 1800, Bethesda, Maryland 20892-1800. fax: 301-402-0491
    • ,
  • Jay H. Hoofnagle

      Affiliations

    • Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Received 30 July 2009 ,Accepted 10 March 2010.

References 

  1. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839–1850
  2. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C (International Hepatitis Interventional Therapy Group). N Engl J Med. 1998;339:1493–1499
  3. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus (International Hepatitis Interventional Therapy Group (IHIT)). Lancet. 1998;352:1426–1432
  4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C (Hepatitis Interventional Therapy Group). N Engl J Med. 1998;339:1485–1492
  5. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology. 2003;310:333–342
  6. Maag D, Castro C, Hong Z, Cameron CE. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem. 2001;276:46094–46098
  7. Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999;30:376–382
  8. Contreras AM, Hiasa Y, He W, et al. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol. 2002;76:8505–8517
  9. Lutchman G, Danehower S, Song BC, et al. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology. 2007;132:1757–1766
  10. Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol. 2003;77:5933–5947
  11. Liu WL, Su WC, Cheng CW, et al. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus. J Infect Dis. 2007;196:425–434
  12. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology. 2007;46:1548–1563
  13. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–972
  14. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103–107
  15. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology. 2004;126:703–714
  16. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature. 2004;432:922–924
  17. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 2003;37:1351–1358
  18. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology. 2007;46:16–21
  19. Jessner W, Gschwantler M, Steindl-Munda P, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet. 2001;358:1241–1242
  20. Tsubota A, Arase Y, Someya T, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol. 2005;75:27–34
  21. Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G. Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis. 2009;49:498–506
  22. Lindh M, Alestig E, Arnholm B, et al. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol. 2007;45:2439–2445
  23. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007;13:2422–2428
  24. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol. 2002;71:669–676
  25. Rahman F, Heller T, Sobao Y, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40:87–97
  26. Taylor MW, Tsukahara T, Brodsky L, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol. 2007;81:3391–3401
  27. Diago M, Castellano G, Garcia-Samaniego J, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006;55:374–379
  28. Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194:895–903
  29. Sarasin-Filipowicz M, Oakeley EJ, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A. 2008;105:7034–7039

 Conflicts of interest This author discloses the following: Dr Feld reports being a member of the advisory board for Roche Canada and Schering-Plough Canada. The remaining authors disclose no conflicts.

 Funding This research was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases.

PII: S0016-5085(10)00392-6

doi: 10.1053/j.gastro.2010.03.037

Gastroenterology
Volume 139, Issue 1 , Pages 154-162.e4 , July 2010

Article Tools

* Image Usage & Resolution